Commonwealth Equity Services LLC Has $300,000 Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Commonwealth Equity Services LLC trimmed its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 9.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,448 shares of the company’s stock after selling 4,217 shares during the period. Commonwealth Equity Services LLC’s holdings in GoodRx were worth $300,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of GDRX. Legato Capital Management LLC bought a new position in shares of GoodRx during the 2nd quarter worth about $805,000. Liontrust Investment Partners LLP purchased a new position in GoodRx in the 2nd quarter valued at approximately $520,000. Beacon Capital Management LLC purchased a new position in GoodRx in the 1st quarter valued at approximately $28,000. California State Teachers Retirement System boosted its holdings in GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after purchasing an additional 3,444 shares during the period. Finally, EntryPoint Capital LLC boosted its holdings in GoodRx by 165.2% in the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after purchasing an additional 11,548 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.17% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Citigroup lowered their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research note on Friday, August 9th. UBS Group decreased their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Finally, Morgan Stanley lifted their price target on shares of GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.36.

GoodRx Trading Down 2.6 %

Shares of NASDAQ:GDRX opened at $6.73 on Tuesday. GoodRx Holdings, Inc. has a 12-month low of $4.14 and a 12-month high of $9.26. The business’s fifty day simple moving average is $7.97 and its 200-day simple moving average is $7.59. The company has a market capitalization of $2.53 billion, a PE ratio of -673.00, a P/E/G ratio of 3.55 and a beta of 1.38. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business’s revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.02 EPS. As a group, equities research analysts predict that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.